by Haja Mo April 15, 2023 Politics The Supreme Court returns to an issue that has divided it before: the use of mifepristone and when to defer to the FDA’s authority. Previous Story Trump details business holdings in belated financial disclosure Next Story Mike Pompeo won’t run for president in 2024, says future run possible